

CReMEC initiative: Establishment and characterization of new in vivo models of human colorectal cancers.

Diane Goéré^{1,4}, Pascale Mariani^{2,4}, Marc Pocard^{3,4}, Ludovic Bigot^{1,4}, Fariba Nemati^{2,4}, Denis Lantuas^{3,4}, Loïc Morgand⁹, Ludovic Lacroix^{1,4}, Sylvia Julien⁷, Grégoire Prévost⁷, Patrick Gonin^{1,4}, Virginie Dangles-Marie^{2,3,4}, Alain Pierré⁶, Alain Bruno⁶, Hugues De Thé^{8,4}, Hany Soliman^{8,4}, Ana Merino-Trigo⁵, Guillaume Lardier⁵, Hervé Rique⁵, Brigitte Demers⁵, Cyril Berthet⁹, Olivier Duchamp⁹,



ASSISTANCE ASSISTANCE

1Institut Gustave Roussy, Villejuif, 2Institut Curie, 3Hôpital Lariboisière, 4Cancéropôle Ile de France, 5sanofi-aventis, Paris, 6Institut de recherche Servier, Croissy sur Seine, 7Ipsen, 8Hôpital St-Louis, Paris, 9Oncodesian, Diion, France


INTRODUCTION - OBJECTIVES

New well characterized models representing the heterogeneity of human colorectal cancers (CRC) are needed to develop effective therapeutic agents for that indication: establishment of such tools will allow a better prediction of the clinical outcome, taking into account the diversity of each patient tumor phenotype and genotype. For this purpose we have associated efforts from hospitals, academic groups, biotech and private pharmaceutical companies. The goal of this consortium is to create an experimental tumor model resource center to improve or strengthen drug development. We report here our results on our fully characterized CRIC004M human colon tumor model.

METHODOLOGY


Clinical data collection

Histological characterization



narmacological (in vivo, ex vivo, 3 selected standards of care)


From May 2007 to December 2008, 87 surgical specimens were collected from CRC patients, and grafted in 32% KRAS mutation rate on clinical samples, a mutation rate in accordance with literature data.



CRIC004M: The 1st characterized model

Clinical data

adenocarcinoma of the left colon of a 70 year old man. His liver metastasis was resected 4 months after left hemicolectomy and 6 cycles of FOLFIRI (folinic acid, fluorouracil, irinotecan). After liver surgery, he received 6 adjuvant cycles of FOLFIRI. He is still alive without disease (follow-up of 18 months).






Histological evaluation reveals a well differentiated adenocarcinoma of the colon, characterized by the presence of glandular structures.

There is a high degree of similarity between xenografts (B, C, D, & E) and patient tumor sample (A). This is in contrast with the histological findings observed in xenograft obtained from commercially available, immortalized colon tumor cell lines (F, G, & H)


There is a high degree of similarity in histological findings regardless of the in vivo passages (B & C).

There is a high degree of similarity in histological findings regardless of the mouse strains (SCID vs Nude ; B & C) or the animal species (mouse vs rat; BD&F



No maior deviation of the genomic profile was demonstrated between patient tumor sample and xenograft model after 8 passages. We noticed only few variations in chromosomes 1 and 17.

Pharmacological characterization



When evaluated ex vivo, only SN-38 induced significant apoptosis and inhibition of tumor cell proliferation on CRIC004N fragments

When evaluated in vivo, only CPT-11 showed moderate antitumor activity in SCID mice at tested dose. Same pharmacological profil was obtained in Nude rats (data not shown)

CONCLUSIONS

- Over a 1.5 year period, the CReMEC consortium was able to graft 87 CRC primary tumor samples into immunodeficient mice, with a take rate >50%. All established models are under characterization with the same process as described in this poster.
- The diversity of the CRC xenografts established is similar to that of the patient tumor samples collected, indicating good representation of the initial population. The preliminary KRAS mutation rate evaluation of 32% is in accordance with that of the literature for colon cancer.
- Characterization of the 1st established model CRIC004M indicate the following:
 - Histological glandular structures are maintained after engraftment into animals.
 - Histological & molecular characterization indicate that the model is stable over at least 8 passages.
 - Molecular characterization suggest a Group 3 classification of CRIC004M based on Jass et al. (Histopathology 2007)
- Initial pharmacological evaluation suggests correlation between ex vivo and in vivo drug response.
- Evaluation on additional models are needed to establish the relevance of such models for the development of anticancer drugs.

median T VOL-DY - median T VOL-DX X 100 AT/C <42 % · Moderate required to declare activity Whoro: ΔT/C <10 % : Marked antitumor activity

RESULTS


Tumor collection

	Primary	Metastasis	Carcinosis	Total
Collected	58	20	9	87
Established in Nude mice	31	16	4	51
Take Rate	53%	80%	44%	58%

immunodeficient mice, with an overall take rate > 50%. Preliminary molecular characterizations indicate a

CRIC004M sample was obtained from a liver metastasis, synchronous of a well differentiated Lieberkühnien

Histological characterization







median C VOL- DY - median C VOL-DX

CGH array analysis; Evaluation of genome-wide, gene copy number was evaluated using a 244k CGH array Agilent technology. It was carried out on DNA from the patient sample (P0) or at an early passage (P1), and at the passage used for the pharmacological evaluation (P8-9),

Relevant clinical information are collected by the attending physician and included in a standardized data sheet. Identification of the data sheet is anonymous

- DNA sequencing: The following genetic markers, relevant in CRC, were selected for sequencing: APC (exons 9 & 16), KRAS (exons 2 & 3), BRAF (exons 11 & 15). TP53 (exons 2 to 11), CTNNB1 (exon 3), PIK3CA (exons 10 to 21), and FBXW7 (exons 3 to 10). Sanger direct sequencing was performed after PCR amplification of exons of genes harboring hotspot mutations as described in Catalogue Of Somatic Mutations In Cancer (COSMIC: http://www.sanger.ac.uk/genetics/CGP/cosmic/
- > Determination of Microsatellite Instability (MSI) status; The MSI status was determined according to the Conference Consensus (or Revised Bethesda Guidelines) (J. Natl Cancer Inst 2004, 96, 261-268) recommendations using the following five quasimonomorphic markers: NR21, BAT26, BAR25, NR24 and NR22.

Pharmacological characterization

AT/C (%) =

- Tested agents: 5-fluorouracii (5-FU), oxaliplatin (L-OHP), irinotecan (CPT-11) or SN-38 for ex vivo evaluation, were tested.
- > 3D ex vivo assay: Two to 4 mm3 tumor fragments were incubated in poly (2-hydroxy ethyl methacrylate)-coated plates for 24h with either DMA vehicle control, 5-FU 1µM, SN-38 1µM or L-OHP 1µM. After 3 days of release without drugs, tumor fragment were paraffin wax embedded and proceeded for Ki67 and M30 immunohistochemistry, Number of Ki67- and M30-positive cells was evaluated to estimate drug effect on proliferation and apoptosis, respectively.

In vivo determination of antitumor activity: Tumor fragments were subcutaneously xenografted in SCID mice. Tumor-bearing mice were randomized when the mean tumor volume reached 100-200 mm3 in mice. Compounds were formulated in glucose 5% in water, administered IV, and tested at 70% of their respective highest non toxic dose and using the following regimen: 5-FU at 56 mg/kg/adm once daily, twice, 4 days apart, L-OHP at 5 mg/kg/adm once daily, twice, 4 days apart and CPT-11 at 30 mg/kg/adm, once daily, thrice, 2 days apart. Antitumor activity was evaluated by calculating the AT/C ratio

penicillin, 200 µg/mL streptomycin and 2.5 µg/mL fungizone. Initial xenografting was carried out at the site of sampling, within 12 hours after specimen collection. Procedures were performed according to ethical guidelines for animal care and handling. 20-40 mg fragments were xenografted subcutaneously either in the flank or in the interscapular area, in 3-5 immunodeficient SWISS Nude mice Grafted mice were kept for a maximum of 4 months without tumor growth